Efficacy and Safety of Daratumumab in a Frail Real-Life Relapsed or Refractory Systemic Light-Chain Amyloidosis Population (AL): Report on 15 Cases from the North of France
Blood (2018) 132 (Supplement 1): 5660.
Currently there are no citedby results. Try again later.
